These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Synthesis and biological evaluation of novel N Nirogi RV; Bandyala TR; Gangadasari PR; Khagga M J Enzyme Inhib Med Chem; 2016; 31(sup1):1-15. PubMed ID: 27806648 [TBL] [Abstract][Full Text] [Related]
25. Anti-Alzheimer's multitarget-directed ligands with serotonin 5-HT Marcinkowska M; Bucki A; Panek D; Siwek A; Fajkis N; Bednarski M; Zygmunt M; Godyń J; Del Rio Valdivieso A; Kotańska M; Kołaczkowski M; Więckowska A Arch Pharm (Weinheim); 2019 Jul; 352(7):e1900041. PubMed ID: 31162703 [TBL] [Abstract][Full Text] [Related]
27. AVN-322 is a Safe Orally Bio-Available Potent and Highly Selective Antagonist of 5-HT6R with Demonstrated Ability to Improve Impaired Memory in Animal Models. Ivachtchenko AV; Ivanenkov YA; Veselov MS; Okun IM Curr Alzheimer Res; 2017; 14(3):268-294. PubMed ID: 27829340 [TBL] [Abstract][Full Text] [Related]
28. Procognitive 5-HT6 antagonists in the rat forced swimming test: potential therapeutic utility in mood disorders associated with Alzheimer's disease. Hirano K; Piers TM; Searle KL; Miller ND; Rutter AR; Chapman PF Life Sci; 2009 Apr; 84(15-16):558-62. PubMed ID: 19302808 [TBL] [Abstract][Full Text] [Related]
29. The role of 5 HT6-receptor antagonists in Alzheimer's disease: an update. Khoury R; Grysman N; Gold J; Patel K; Grossberg GT Expert Opin Investig Drugs; 2018 Jun; 27(6):523-533. PubMed ID: 29848076 [TBL] [Abstract][Full Text] [Related]
30. Progress in Investigational Agents Targeting Serotonin-6 Receptors for the Treatment of Brain Disorders. Nirogi R; Jayarajan P; Shinde A; Mohammed AR; Grandhi VR; Benade V; Goyal VK; Abraham R; Jasti V; Cummings J Biomolecules; 2023 Feb; 13(2):. PubMed ID: 36830678 [TBL] [Abstract][Full Text] [Related]
31. Optimization of N'-(arylsulfonyl)pyrazoline-1-carboxamidines by exploiting a novel interaction site in the 5-HT6 antagonistic binding pocket. van Loevezijn A; Venhorst J; Iwema Bakker WI; Lange JHM; de Looff W; Henzen R; de Vries J; van de Woestijne RP; den Hartog AP; Verhoog S; van der Neut MAW; de Bruin NMWJ; Kruse CG Bioorg Med Chem Lett; 2016 Mar; 26(6):1605-1611. PubMed ID: 26876931 [TBL] [Abstract][Full Text] [Related]
32. Design and synthesis of novel N-sulfonyl-2-indoles that behave as 5-HT Saavedra OM; Karila D; Brossard D; Rojas A; Dupuis D; Gohier A; Mannoury la Cour C; Millan MJ; Ortuno JC; Hanessian S Bioorg Med Chem; 2017 Jan; 25(1):38-52. PubMed ID: 28029458 [TBL] [Abstract][Full Text] [Related]
33. New 1-arylindoles based serotonin 5-HT7 antagonists. Synthesis and binding evaluation studies. Sagnes C; Fournet G; Satala G; Bojarski AJ; Joseph B Eur J Med Chem; 2014 Mar; 75():159-68. PubMed ID: 24531229 [TBL] [Abstract][Full Text] [Related]
34. 5-HT(6) receptor modulators: a patent update. Part 2. Diversity in heterocyclic scaffolds. Ivachtchenko AV; Ivanenkov YA; Skorenko AV Expert Opin Ther Pat; 2012 Oct; 22(10):1123-68. PubMed ID: 22957857 [TBL] [Abstract][Full Text] [Related]
35. Identification of a series of benzoxazoles as potent 5-HT6 ligands. Liu KG; Lo JR; Comery TA; Zhang GM; Zhang JY; Kowal DM; Smith DL; Di L; Kerns EH; Schechter LE; Robichaud AJ Bioorg Med Chem Lett; 2009 Feb; 19(4):1115-7. PubMed ID: 19152787 [TBL] [Abstract][Full Text] [Related]
36. Antagonism of the 5-HT de Jong IEM; Mørk A Neuropharmacology; 2017 Oct; 125():50-63. PubMed ID: 28711518 [TBL] [Abstract][Full Text] [Related]
38. Design, synthesis, and pharmacological evaluation of multitarget-directed ligands with both serotonergic subtype 4 receptor (5-HT4R) partial agonist and 5-HT6R antagonist activities, as potential treatment of Alzheimer's disease. Yahiaoui S; Hamidouche K; Ballandonne C; Davis A; de Oliveira Santos JS; Freret T; Boulouard M; Rochais C; Dallemagne P Eur J Med Chem; 2016 Oct; 121():283-293. PubMed ID: 27266998 [TBL] [Abstract][Full Text] [Related]
39. Design, Synthesis and Biological Investigation of Flavone Derivatives as Potential Multi-Receptor Atypical Antipsychotics. Gao L; Yang Z; Xiong J; Hao C; Ma R; Liu X; Liu BF; Jin J; Zhang G; Chen Y Molecules; 2020 Sep; 25(18):. PubMed ID: 32911828 [TBL] [Abstract][Full Text] [Related]
40. Design and synthesis of novel series of 5-HT6 receptor ligands having indole, a central aromatic core and 1-amino-4 methyl piperazine as a positive ionizable group. Hayat F; Cho S; Rhim H; Indu Viswanath AN; Pae AN; Lee JY; Choo DJ; Choo HY Bioorg Med Chem; 2013 Sep; 21(17):5573-82. PubMed ID: 23810425 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]